Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amphotericin B phosphatidylglycerol complex liposome is an investigational liposomal formulation of the polyene antifungal amphotericin B, developed by Beijing Tide Pharmaceutical. The drug functions by binding to ergosterol, a key component of fungal cell membranes, which leads to the formation of transmembrane pores. These pores cause the leakage of essential intracellular ions and molecules, ultimately resulting in fungal cell death. This specific formulation utilizes a phosphatidylglycerol complex within a liposomal structure to optimize the pharmacokinetic profile and reduce the nephrotoxicity typically associated with conventional amphotericin B deoxycholate. It is being evaluated in clinical trials for the treatment of systemic fungal infections, leishmaniasis, and as empirical therapy for suspected fungal infections in patients with febrile neutropenia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amphotericin B phosphatidylglycerol complex liposome.